Literature DB >> 29021204

The fourth pillar: Despite some setbacks in the clinic, immunotherapy has made notable progress toward becoming an additional therapeutic option against cancer.

Philip Hunter1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29021204      PMCID： PMC5666595          DOI： 10.15252/embr.201745172

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  3 in total

1.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

Authors:  K R Jerome; D L Barnd; K M Bendt; C M Boyer; J Taylor-Papadimitriou; I F McKenzie; R C Bast; O J Finn
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

2.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

3.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

Authors:  Lena M Kranz; Mustafa Diken; Heinrich Haas; Sebastian Kreiter; Carmen Loquai; Kerstin C Reuter; Martin Meng; Daniel Fritz; Fulvia Vascotto; Hossam Hefesha; Christian Grunwitz; Mathias Vormehr; Yves Hüsemann; Abderraouf Selmi; Andreas N Kuhn; Janina Buck; Evelyna Derhovanessian; Richard Rae; Sebastian Attig; Jan Diekmann; Robert A Jabulowsky; Sandra Heesch; Jessica Hassel; Peter Langguth; Stephan Grabbe; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2016-06-01       Impact factor: 49.962
  3 in total
  8 in total

1.  Discovery of a Potent Anticancer Agent PVHD303 with in Vivo Activity.

Authors:  Yumiko Suzuki; Ayana Otake; Satoshi Ueno; Kensuke Hayashi; Hirosuke Ishii; Nao Miyoshi; Kenta Kuroiwa; Masashi Tachikawa; Yuki Fujimaki; Kotaro Nishiyama; Kei Manabe; Ryuta Yamazaki; Akira Asai
Journal:  ACS Med Chem Lett       Date:  2020-05-08       Impact factor: 4.345

2.  Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.

Authors:  Tina C Albershardt; Jardin Leleux; Andrea J Parsons; Jordan E Krull; Peter Berglund; Jan Ter Meulen
Journal:  NPJ Vaccines       Date:  2020-06-16       Impact factor: 7.344

3.  Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review.

Authors:  Anastasios Kyriazoglou; Maria Kaparelou; Georgios Goumas; Michael Liontos; Roubini Zakopoulou; Eleni Zografos; Anna Zygogianni; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Breast Care (Basel)       Date:  2021-03-29       Impact factor: 2.860

Review 4.  Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy.

Authors:  Fanfei Meng; Jianping Wang; Yoon Yeo
Journal:  J Control Release       Date:  2022-03-26       Impact factor: 11.467

5.  Drug Conjugates for Targeting Eph Receptors in Glioblastoma.

Authors:  Puja Sharma; Callie Roberts; Denise Herpai; Izabela D Fokt; Waldemar Priebe; Waldemar Debinski
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-23

6.  Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.

Authors:  Tina C Albershardt; Jardin Leleux; Andrea J Parsons; Jordan E Krull; Peter Berglund; Jan Ter Meulen
Journal:  NPJ Vaccines       Date:  2020-06-16       Impact factor: 7.344

7.  T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.

Authors:  John C Flickinger; Jagmohan Singh; Yanki Yarman; Robert D Carlson; Joshua R Barton; Scott A Waldman; Adam E Snook
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 8.786

Review 8.  Receptor-Targeted Glial Brain Tumor Therapies.

Authors:  Puja Sharma; Waldemar Debinski
Journal:  Int J Mol Sci       Date:  2018-10-25       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.